[1] ANDREASSEN O A, DJUROVIC S, THOMPSON W K, et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors[J]. Am J Hum Genet, 2013,92(2):197-209. [2] de HERT M, CORRELL C U, BOBES J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care[J]. World Psychiatry, 2011,10(1):52-77. [3] FOGUET-BOREU Q, FERNANDEZ SAN MARTIN M I, FLORES MATEO G, et al. Cardiovascular risk assessment in patients with a severe mental illness: a systematic review and meta-analysis[J]. BMC Psychiatry, 2016,16:141. [4] D'AGOSTINO R B, VASAN R S, PENCINA M J, et al. General cardiovascular risk profile for use in primary care: the framingham heart study[J]. Circulation, 2008,117:743-753. [5] 杨东英, 陆小兵, 李佑辉,等. 亚甲基四氢叶酸还原酶基因多态性和血浆同型半胱氨酸水平与首发精神分裂症的关系[J]. 中华行为医学与脑科学杂志,2007,16(10):901-902. [6] 易峰, 毛静宇, 张洋洋,等. 精神分裂症患者血浆同型半胱氨酸水平的Meta分析[J]. 中国神经精神疾病杂志,2013,39(8):463-468. [7] SIAW-CHEOK L, ESHA DAS G. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases[J]. Eur J Med Genet, 2015,58(1):1-10. [8] 李建平, 卢新政, 霍勇,等. H型高血压诊断与治疗专家共识[J]. 中华高血压杂志,2016,8(3):243-248. [9] 中华医学会精神病学分会. 中国精神障碍分类与诊断标准第三版(精神障碍分类)[J]. 中华精神科杂志,2001,34(3):184-188. [10] 中国高血压防治指南修订委员会. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志,2019,19(1):6-49. [11] 王国强. 《全国精神卫生工作规划(2015-2020年)》解读[J]. 中国实用乡村医生杂志,2016,10(1):43-46. [12] TURNER T H. Long term outcome of treating schizophrenia[J]. BMJ, 2004,329(7474):1058-1059. [13] TIIHONEN J, LONNQVIST J, WAHLBECK K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)[J]. Lancet, 2009,374(9690):620-627. [14] FRCP R H, FRCPSYCH R P D. Diabetes and cardiovascular risk in severe mental illness: a missed opportunity and challenge for the future[J]. Pract Diab, 2011,27(2):79-84. [15] CORRELL C U, FREDERICKSON A M, KANE J M, et al. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics[J]. Bipolar Disord, 2008,10(7):788-797. [16] de H M, SCHREURS V, VANCAMPFORT D, et al. Metabolic syndrome in people with schizophrenia: a review[J]. World Psychiatry, 2009,8(1):15-22. [17] TAY Y H, NURJONO M, LEE J. Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia[J]. Schizophr Res, 2013,147(1):187-192. [18] 赵帅, 周晓琴, 夏海龙,等. 住院精神分裂症患者心血管疾病发生风险研究[J]. 中国神经精神疾病杂志,2017,43(9):539-543. [19] FENG L G, SONG Z W, XIN F, et al. Association of plasma homocysteine and methylenetetrahydrofolate reductase C677T gene variant with schizophrenia: a chinese han population-based case-control study[J]. Psychiatry Res, 2009,168(3):205-208. [20] OSBORN D P, SARAH H, OMAR R Z, et al. Cardiovascular risk prediction models for people with severe mental illness: results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program[J]. JAMA Psychiatry, 2015,72(2):143-151. [21] van W R, RUTTEN B P, PEERBOOMS O, et al. MTHFR and risk of metabolic syndrome in patients with schizophrenia[J]. Schizophr Res, 2010,121(1-3):193-198. |